Impax Asset Management Group plc Acquires 421,252 Shares of Avantor, Inc. (NYSE:AVTR)

Impax Asset Management Group plc lifted its stake in Avantor, Inc. (NYSE:AVTR) by 30.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,789,610 shares of the company’s stock after buying an additional 421,252 shares during the period. Impax Asset Management Group plc owned approximately 0.26% of Avantor worth $37,707,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Creative Planning grew its holdings in shares of Avantor by 54.0% during the 3rd quarter. Creative Planning now owns 28,136 shares of the company’s stock worth $728,000 after purchasing an additional 9,866 shares in the last quarter. Sequoia Financial Advisors LLC bought a new position in Avantor in the 3rd quarter valued at about $255,000. Louisiana State Employees Retirement System acquired a new position in shares of Avantor in the 3rd quarter valued at approximately $4,874,000. Forsta AP Fonden lifted its holdings in shares of Avantor by 7.0% during the 3rd quarter. Forsta AP Fonden now owns 146,900 shares of the company’s stock worth $3,800,000 after acquiring an additional 9,600 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Avantor by 4.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 28,012 shares of the company’s stock worth $725,000 after acquiring an additional 1,091 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Price Performance

AVTR stock opened at $17.31 on Monday. The company has a market capitalization of $11.78 billion, a P/E ratio of 16.64, a price-to-earnings-growth ratio of 1.57 and a beta of 1.28. Avantor, Inc. has a 52-week low of $17.14 and a 52-week high of $28.00. The business has a 50-day simple moving average of $20.96 and a two-hundred day simple moving average of $22.93. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.70 and a current ratio of 1.07.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period last year, the company posted $0.22 earnings per share. Research analysts expect that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AVTR has been the topic of a number of research analyst reports. Morgan Stanley cut their target price on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Raymond James restated an “outperform” rating and issued a $24.00 price target (down previously from $26.00) on shares of Avantor in a research report on Monday, February 10th. Robert W. Baird decreased their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Wells Fargo & Company dropped their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, UBS Group reissued a “neutral” rating and issued a $25.00 price objective (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.92.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.